CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31

CareDx, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$67.08+3.08 (+4.81%)

Close on Oct 19, 2026

Market cap: $3.58B
P/E (TTM): 32.4
Dividend yield: –

CareDx, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	380	334	280	322	296	192	127	77	48	41	28	27	22	20
Cost of Revenue	–	–	–	–	–	–	45	33	21	10	0	0	9.08	7.93
Gross Profit	–	–	–	–	–	–	82	44	27	30	28	27	13	13
Research & Development	71	73	82	90	77	49	31	15	12	12	9.33	3.85	3.18	4.75
Selling, General & Admin	210	207	203	196	152	103	75	45	33	32	21	15	11	10
Selling & Marketing	103	82	84	96	77	54	39	22	13	11	8.35	6.47	5.89	5.42
General & Administrative	108	125	119	100	75	49	37	23	20	21	12	8.44	4.81	4.69
Operating Expenses	411	293	484	399	326	215	152	92	47	78	40	26	23	23
Operating Income	-31	41	-203	-77	-30	-23	-25	-16	-20	-37	-12	1.25	-0.86	-2.34
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	0.63
Other Non-Operating Income	9.70	12	13	1.00	-2.36	2.78	0.59	-33	-37	-1.92	-0.19	-0.08	-0.54	-0.01
Merger & Restructuring Charges	–	1.78	2.32	0	0	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	2.26	0	0	0.84	2.44	0	0.16	0	1.96	13	0	0	–	–
Gain (Loss) on Investments	0	0	2.11	0	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.05	-0.09	-0.04	0	0	0	-0.16	0	-0.01	0	0.00	0	0	–
Legal Settlements	-5.71	96	-96	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-21	53	-190	-76	-32	-20	-24	-48	-57	-41	-14	-0.72	-3.54	-5.06
Income Tax Expense	0.27	0.31	0.14	0.38	-1.43	-1.04	-1.98	-1.43	-1.71	-1.61	0	-1.50	0	0
Net Income incl. Noncontrolling Interests	–	–	–	–	-31	-19	-22	-47	-56	-40	-14	0.78	–	–
Minority Interest in Earnings	–	–	–	–	–	0	0	-0.03	-0.09	-0.29	0	0	–	–
Net Income	-21	53	-190	-77	-31	-19	-22	-47	-55	-39	-14	0.78	-3.54	-5.06
Net Income to Common	-21	53	-190	-77	-31	-19	-22	-47	-55	-39	-14	0.91	-3.54	-5.06
EPS (Basic)(per share)	-0.40	1.00	-3.54	-1.44	-0.59	-0.40	-0.52	-1.31	-2.38	-2.39	-1.16	0.13	-3.50	-5.01
EPS (Diluted)(per share)	-0.40	0.93	-3.54	-1.44	-0.59	-0.40	-0.52	-1.31	-2.38	-2.39	-1.16	0.10	-3.50	-5.01
Shares Outstanding (Basic, Weighted)(shares)	53	53	54	53	52	46	42	36	23	16	12	5.82	1.01	1.01
Shares Outstanding (Diluted, Weighted)(shares)	53	57	54	53	52	46	42	36	23	16	12	9.28	1.01	1.01
EBITDA	-16	55	-189	-66	-21	-16	-19	-11	-17	-34	-11	1.76	-0.19	-1.27
Net Interest Income	–	–	–	–	–	–	–	–	–	-1.86	-1.59	-2.12	-2.15	-2.70

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 23.6%
Net margin: 24.2%
Return on equity, FY2025: -6.3%

Financial strength

Current ratio: 4.58
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 398.8%

Valuation

P/E ratio: 32.4
Price to sales: 7.82
Price to book: 8.42
Dividend yield: –